Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN71079188
ISRCTN71079188
Completed
未知

The pharmacogenetics of aspirin resistance

Royal Group of Hospitals Trust (UK)0 sites150 target enrollmentMarch 14, 2007
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Royal Group of Hospitals Trust (UK)
Enrollment
150
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 14, 2007
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional

Investigators

Sponsor
Royal Group of Hospitals Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • •Healthy individuals aged between 18 to 60 years

Exclusion Criteria

  • •Current exclusion criteria as of 01/10/2012
  • •1\. Use of other anti\-platelet drugs (thienopyridines, GPIIb/IIIa antagonists, dipyridamole) because these drugs would interfere with platelet function assays
  • •2\. Use of other non\-steroidal anti\-inflammatory drugs, because of the pharmacodynamic interactions
  • •3\. History of dyspepsia or peptic ulceration requiring treatment with proton pump inhibitors/H2 antagonists, in view of the increased risk of gastrointestinal haemorrhage
  • •4\. History of systemic inflammatory diseases, in view of the need for these patients to take anti\-inflammatory drugs
  • •5\. History of asthma
  • •6\. Use of other aspirin\-containing medications (including herbal preparations)
  • •7\. Family or personal history of bleeding disorders
  • •8\. Use of oral anticoagulants
  • •9\. Platelet count outside the normal range (150,000 to 450,000/ml)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
The Pharmacogenetics of Aspirin Resistance - The Pharmacogenetics of Aspirin ResistanceAspirin resistance: Vascular diseases are common problems and aspirin is used as an anti-platelet drug to prevent thrombosis. However, aspirin's anti-platelet effect may not be uniform in all patients. From a biochemical perspective, aspirin resistance refers to patients who do not display an adequate degree of platelet inhibition on formal laboratory tests. Published data suggest that 5 - 45% of patients are 'aspirin resistant'. The mechanisms of aspirin resistance are poorly understood.
EUCTR2006-001232-42-GBRoyal Group of Hospitals Trust150
Completed
Not Applicable
Genotypic and Phenotypic Correlates of Resistance to AspirinPlatelet Dysfunction Due to Aspirin
NCT01361620George Washington University190
Completed
Not Applicable
Efficacy of aspirin desensitization in nasal polyposisnasal polyp.Polyp of nasal cavity
IRCT2016070728821N1Vice chancellor for research, Shahid Beheshti University of Medical Sciences34
Completed
Not Applicable
Evaluation of aspirin resistance in different doses of aspiriAspirin resistance.Salicylates
IRCT201202026958N3orestan University of Medical Sciences370
Active, not recruiting
Not Applicable
Aspirin resistance and heart disease - Aspirin resistance
EUCTR2009-017176-25-GBSandwell and West Birmingham NHS Trust